{"entity": "publication", "iuid": "fe921e2378684f9481a899c6393cada6", "timestamp": "2026-09-26T00:12:26.026Z", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/fe921e2378684f9481a899c6393cada6.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/fe921e2378684f9481a899c6393cada6"}}, "title": "Secondary malignancies among mantle cell lymphoma patients.", "authors": [{"family": "Abalo", "given": "Kossi D", "initials": "KD"}, {"family": "Smedby", "given": "Karin E", "initials": "KE"}, {"family": "Ekberg", "given": "Sara", "initials": "S"}, {"family": "Eloranta", "given": "Sandra", "initials": "S"}, {"family": "Pahnke", "given": "Simon", "initials": "S"}, {"family": "Albertsson-Lindblad", "given": "Alexandra", "initials": "A"}, {"family": "Jerkeman", "given": "Mats", "initials": "M"}, {"family": "Glimelius", "given": "Ingrid", "initials": "I"}], "type": "journal article", "published": "2023-12-00", "journal": {"title": "Eur. J. Cancer", "issn": "1879-0852", "volume": "195", "pages": "113403", "issn-l": "0959-8049"}, "abstract": "With modern treatments, mantle cell lymphoma (MCL) patients more frequently experience long-lasting remission resulting in a growing population of long-term survivors. Follow-up care includes identification and management of treatment-related late-effects, such as secondary malignancies (SM). We conducted a population-based study to describe the burden of SM in MCL patients.\n\nAll patients with a primary diagnosis of MCL, aged \u2265 18 years and diagnosed between 2000 and 2017 in Sweden were included along with up to 10 individually matched population comparators. Follow-up was from twelve months after diagnosis/matching until death, emigration, or December 2019, whichever occurred first. Rates of SM among patients and comparators were estimated using the Anderson-Gill method (accounting for repeated events) and presented as hazard ratios (HR) with 95% confidence intervals (CI) adjusted for age at diagnosis, calendar year, sex, and the number of previous events.\n\nOverall, 1 452 patients and 13 992 comparators were followed for 6.6 years on average. Among patients, 230 (16%) developed at least one SM, and 264 SM were observed. Relative to comparators, patients had a higher rate of SM, HRadj= 1.6 (95%CI:1.4-1.8), and higher rates were observed across all primary treatment groups: the Nordic-MCL2 protocol, R-CHOP, R-bendamustine, ibrutinib, lenalidomide, and R-CHOP/Cytarabine. Compared to Nordic-MCL2, treatment with R-bendamustine was independently associated with an increased risk of SM, HRadj= 2.0 (95%CI:1.3-3.2). Risk groups among patients were those with a higher age at diagnosis (p < 0.001), males (p = 0.006), and having a family history of lymphoma (p = 0.009). Patients had preferably higher risk of melanoma, other neoplasms of the skin and other hematopoietic and lymphoid malignancies.\n\nMCL survivors have an increased risk of SM, particularly if treated with R-bendamustine. The intensive treatments needed for long-term remissions are a concern, and transition to treatment protocols with sustained efficacy but with a lower risk of SM is needed.", "doi": "10.1016/j.ejca.2023.113403", "pmid": "37952281", "labels": [], "xrefs": [{"db": "pii", "key": "S0959-8049(23)00705-0"}], "notes": [], "created": "2026-09-23T11:23:55.830Z", "modified": "2026-09-23T11:23:55.844Z"}